Skip to main content
NewslettersWatchlist

United Therapeutic(UTHR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low385.47
Day High401.53
Open:400.45
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans.
Barchart
Chart of the Day: United Therapeutics - Drugs for Chronic Illnesses
Barchart
Markets Today: Stocks Fall as Fitch Cuts its U.S. Debt Rating
MarketBeat
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Business Wire
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
Business Wire
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
The Globe and Mail
13 U.S. health care stocks starting to shine again
Business Wire
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
Business Wire
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
Barchart
Markets Today: Stocks Climb Ahead of FOMC Minutes
Business Wire
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023
Business Wire
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2023
Barchart
Pre-Market Brief: Stocks Mixed As Labor Market Strength Weigh On Sentiment
Business Wire
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
Business Wire
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
Business Wire
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
Business Wire
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
Business Wire
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis

Profile

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.